Safety, clinical activity and biomarker results from a Phase Ib study of erlotinib plus atezolizumab in advanced NSCLC
Refereed conference paper presented and published in conference proceedings

香港中文大學研究人員

全文

其它資訊
著者RUDIN M Charles, CERVANTES Andres, DOWLATI Afshin, BESSE Benjamin, MA Buig Yue Brigette, COSTA Danniel, SCHMID Peter, HEIST Rebecca, VILLAFLOR Victoria, SARKAR Indrani, HUSENI Mahrukh, FOSTER Paul
會議名稱17th World Conference on Lung Cancer 2016, 4–7 December 2016, Vienna, Austria
會議開始日04.12.2016
會議國家/地區奧地利
會議論文集題名17th World Conference on Lung Cancer 2016, 4–7 December 2016, Vienna, Austria
出版年份2016
月份12
日期4
出版地Austria, Vienna
頁次one
語言英式英語
關鍵詞biomarker; atezolizumab

上次更新時間 2018-22-01 於 20:46